CytomX Therapeutics Inc (CTMX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $444.73M
Last updated: Nov 17, 2026 at 4:34 PM ET
CytomX Therapeutics Inc (CTMX) Stock Chart
CytomX Therapeutics (CTMX) has a latest price of $1.94 on Nov 17, 2026, 76.4% below its 52-week high of $8.21. Its price fell 50.0% over the past 12 months. The month-end price fell 79.2% over the 10 years through Oct 2026, a compound annual decline of 14.5%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $29.71 in Feb 2018 and its lowest $0.64 in Mar 2025, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart CTMX with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for CTMX.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 45.7%, and over 6 months it fell 46.7%. The month-end price rose 112.7% over the 3 years through Oct 2026, a compound annual rate of 28.6%.
| Period | Change |
|---|---|
| 1 month | -17.1% |
| 3 months | -45.7% |
| 6 months | -46.7% |
| 12 months | -50.0% |
| 12 months, with dividends | -50.0% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +112.7% | +28.6% |
| 5 years | -60.5% | -17.0% |
| 10 years | -79.2% | -14.5% |
Price by Year
Its best calendar year was 2025, when the price rose 313.6%, and its weakest was 2022, when it fell 63.0%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $2.34 | -45.1% |
| 2025 | $4.26 | +313.6% |
| 2024 | $1.03 | -33.5% |
| 2023 | $1.55 | -3.1% |
| 2022 | $1.60 | -63.0% |
| 2021 | $4.33 | -33.9% |
| 2020 | $6.55 | -21.2% |
| 2019 | $8.31 | -45.0% |
| 2018 | $15.10 | -28.5% |
| 2017 | $21.11 | +92.1% |
Trading Range
The price is 22.3% below its 50-day average of $2.50 and 47.1% below its 200-day average of $3.67.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $1.94 | |
| 52-week high | $8.21 | -76.4% |
| 52-week low | $1.90 | +2.1% |
| 50-day average | $2.50 | -22.3% |
| 200-day average | $3.67 | -47.1% |
Price Risk
Over 3 years, its largest fall from a peak was 91.6%.
| Measure | Value |
|---|---|
| 1-year beta | 1.53 |
| Largest fall, 1 year | -71.3% |
| Largest fall, 3 years | -91.6% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About CTMX
What is CTMX's 1-year price change?
CytomX Therapeutics's price fell 50.0% over the past 12 months. With dividends included, the 12-month total return was -50.0%.
What is CTMX's 5-year price change?
CytomX Therapeutics's month-end price fell 60.5% over the 5 years through Oct 2026, a compound annual decline of 17.0%. These figures leave out dividends.
What is CTMX's 52-week high and low?
CytomX Therapeutics's 52-week high is $8.21 and its 52-week low is $1.90. Its latest price of $1.94 on Nov 17, 2026 is 76.4% below the high.
What is CTMX's beta?
CytomX Therapeutics's 1-year beta against the S&P 500 is 1.53, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 71.3%.
Is the CTMX chart free?
Yes. Advanced Charting for CTMX is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
CTMX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors